The blood gene expression signatures are used as biomarkers for immunological and nonimmunological diseases.
Introduction
In this paper, we examine a general question: whether a drug aiming to perturb a disease phenotype should target genes whose expression is dominated by heritable or non-heritable factors?
The expression level of a gene is determined by both heritable effects and non-heritable effects. We estimated those effects for expressions of 3245 genes from MuTHER twin database (in Figure 1) and found that the expression of most genes are driven by non-heritable effects. 5 At first, we would expect that a gene that is significantly impacted by non-heritable effects would be more likely to be affected by a drug -drugs could take advantage of such gene's environmentally driven variability.
Naturally, heritable factors also play an important role in drug response. [6] [7] [8] In our study, we find that the strong heritable effects on a gene's expression are predictive of whether drugs can influence this gene. A simple experiment in Section 3.2 uses CMap database to show that genes robust to non-heritable effects -hence, strongly driven by heritable effects -are more likely to be part of a drug influenced gene expression signature.
The result of this experiment led us to examine the first question in a broader context of gene regulatory network. Previous studies show that genes can pass the drug influence through the biological network to induce change in a target gene. 9, 10 We deem such genes source genes, as they can be seen as sources of drug effect propagation in the network. Hence, we wondered whether we can predict the flow of drug influence through a regulatory network from source to target genes.
We say that there exists a regulation flow between a source gene and a target gene if there is a sequence of strong regulatory relationships leading from the source gene to the target gene. Naturally, highly variable source gene with a strong flow to target gene will induce variance in the target gene. We can estimate how much of the heritably or non-heritably driven variance is propagated from source to target. Consequently, we introduced quantitative measures of strength of heritable or non-heritable flow between source and target genes.
We call a regulation flow between a source and a target gene drug influence flow if there exists a drug influencing both genes. Hence we can pose a question: Does a strong heritable flow between source and a target imply existence of a drug influence flow between these two genes?
An experiment in Section 3.3 reveals the fact: strong heritable flows are predictive of drug influence flows. Equally importantly, strong non-heritable flows are not predictive of drug influence flows. Hence, a drug influence flow leading to particular target gene is best identified through the regulation flows propagating substantial heritable effects.
Here, we provide a simple example of this relationship in Figure 2 . In this example, both the source gene PI4KB and PIK3R5 have regulation flow to target gene INPP5F. However, heritable flow strength to INPP5F from PI4KB (red) is higher than heritable flow strength from PIK3R5, even though they have similar regulation flow strength. Our validation in CMap shows that there is no drug influencing both PIK3R5 and INPP5F; while the drug "phthalylsulfathiazole" is known to influence both PI4KB and INPP5F. The rest of this paper is organized as follows: we introduce methods to find the drug influence flows in a specific network and Twin-ACE model for heritable effects estimation in Section 2. Supportive experiments and results are discussed in Section 3 and 4.
Methods
In this section, we discuss the methods that we use to recover the regulatory network and estimate heritable and non-heritable effects. In Section 2.1, we first introduce the directed acyclic graph gene regulatory network and the parameter estimation of a given network using linear model. In the second part, we introduce Twin-ACE model that we are using to estimate the impact of heritable and non-heritable effects on genes' expression, and the quantitative measures of the heritable and non-heritable flow strength in a regulatory network. Twin-ACE model in combination with regulatory network model can be seen as a mixed model of the joint data. ?
DAGRN and its estimation
Directed Acyclic Gene Regulatory Network(DAGRN) Our method operates on a DAGRN, as this representation enables a straightforward way of calculating the regulatory effects using linear regression of expression. Specifically, DAGRN is a graph of P nodes with no loops or undirected edges. Each node t in the graph is a random variable x t represents the measurement of a gene expression value. It has the following conditional probability density:
where pa(t) is the set of parent nodes that link to node t. W is an adjacency matrix of size P × P . Each entry w s,t indicates the strength of edge s → t. µ t is the local mean. We call σ 2 t the residual variance of x t .
Linear model estimation Given a gene expression matrix X of size N × P , where N is the number of samples and P is the number of genes, we can estimate the
Let us look at a specific gene. We use a vector y to denote the N observed samples for that gene. We denote regulators' gene expression matrix as R. This is a matrix of size N × R. Each of R columns is an observed expression levels corresponding to a parent node, a regulator. We can write the joint distribution for all the samples as:
and r k denotes k th row of matrix R. µ is the local mean for y, σ 2 is the residual variance. We can derive the maximum likelihood estimation (MLE) update for parameters in (2) as :
We writeỹ = y − µ MLE 1 N for convenience. The optimization problem (5) is a linear regression problem.
Stimulation-Response Matrix After acquiring the regulation weights for the network, we need to calculate the total regulation influence from any source node to any target node. Therefore, we introduce the Stimulation-Response matrix. To differentiate the notation from µ t , which is the local mean of a gene expression x t , we define α t E[x t ] as the global mean of x t . Suppose the drug treatment changes mean of the source gene x s by ∆α s , we want to know the response change ∆α t in the target gene. For convenience, we will call ∆α s stimulation change and ∆α t response change.
As our model is a Linear-Gaussian model, the stimulation change and response change are also linear: 11 ∆α t = S s,t ∆α s . We call S Stimulation-Response matrix. It is a P × P matrix, where entry (s, t) indicates the response change ∆α t in the target gene t given unit stimulation change (∆α s = 1) in the source gene s. We can use Algorithm 1 to calculate the StimulationResponse matrix. The computational complexity for this method is O(P 2 V ), V is the total edge number. input : W : adjacency matrix, P : total node number output: S : stimulation-response matrix initialize S ← 0 P ×P ; for x ← 1 to P do
for y ← nodes has directed edges link from x do for j ← 1 to P do S j,y ← S j,y + S j,x * W x,y ; end end end Algorithm 1: The algorithm for calculating Stimulation-Response matrix
We call the value in entry (s,t) of S as the regulation flow strength of the regulation flow s → t. We only consider a regulation flows between source gene s and target gene t for which S(s, t) > T , where T is a certain threshold.
Twin-ACE model and heritable/non-heritable effect estimation
We are using the Twin-ACE model to estimate the heritable and non-heritable effects on the phenotypes. The standard ACE model for twin studies is based on the assumption that identical twins share their genes while fraternal twins share approximately half of their polymorphic gene sequences. ACE study design assumes presence of both monozygotic and dizygotic twins. In order to model the relatedness of the gene expression measurements in twins, we utilize the standard ACE model. 12 The main assumption underlying the ACE models is that the covariance of the gene expression in a twin pair can be decomposed into three contributions: 1) Additive genetic component 2) Common environmental component, and 3) twin-specific Environmental component.
The additive genetic component is the only component that is dependent on whether the twins are identical (monozygotic, MZ) or fraternal (dizygotic, DZ). Identical twins share same genetic material and hence differences in their gene expressions are attributable to environmental factors. In contrast, fraternal twins, on average, share only half of their genetic sequences and hence differences in their gene expressions can be attributed to heritable or non-heritable factors. This observation motivates parametrization of phenotypic covariance in terms of additive components A MZ = reflecting the expectation of higher covariance among mono-zygotic twins to the extent the gene expression is heritable. In terms of notation, to indicate zygosity of a twin pair t 1 and t 2 we will use zyg(t 1 , t 2 ), naturally zyg(t 1 , t 2 ) ∈ {MZ, DZ}.
In addition to additive genetic effects, we also model potential environment effects. We denote them as C and E. These effects are assumed to be independent of twins' genomes. Furthermore, the common environmental effects are assumed to be affecting both of the twins in a family, and hence off-diagonal covariance terms are 1. The twin-specific environmental effects are assumed to have an independent effect on each of the twins, so the off-diagonal terms are 0. Hence, we have C = 
Estimation of ACE parameters
where
We call a, c, e ACE parameters for gene expression vector y. We will abbreviate covariances Σ MZ , Σ DZ while acknowledging their dependence on parameters a, c, e. In this model, µ is the population mean of the y. To estimate the parameters a, c, e, we need to solve the follow optimization:
(a, c, e) MLE = argmax a,c,e
This optimization problem can be solved by Newton's method. 13 We define the heritable effects on a gene as a 2 , and the non-heritable effects on a gene as c 2 + e 2 .
Heritable/non-heritable flow strength The total variance propagated through a regulation flow can be decomposed into heritable flow and non-heritable flow. We define the heritable flow strength of a regulation flow s → t as: G(s, t) = a 2 s × S(s, t). G(s, t) indicates how much of heritably driven variance is propagated by the regulation flow from source gene s to target gene t. Similarly, we define non-heritable flow strength E(s, t) = (c 2 s + e 2 s ) × S(s, t)
as the amount of non-heritably driven variance propagated by the regulation flow. Note that the total variance propagated by regulation flow is G(s, t) + E(s, t) = (a 2 + e 2 + c 2 ) × S(s, t). As we standardized all the gene expressions in all our experiments, we have a 2 + e 2 + c 2 = 1, so G(s, t) + E(s, t) = S(s, t). S(s, t) is different for each regulation flow, so we cannot directly compute E(s, t) from G(s, t).
Experiment and Result
In this section, we performed two experiments. An overview of the data source and experiment information is shown in Figure 3 . The pre-processing of the data is discussed at first. The following experiment "Drug target preference" is a significance test for the overlap between genes influenced by drugs and genes driven by strong heritable effects. We found there are more drugs preferring genes driven by strong heritable effects than non-heritable effects.
In the second experiment "Drug influence flows identification", we treat the problem of predicting drug influence flows as a classification problem using heritable, non-heritable and regulation flow strength as the classifier features. Our result shows that heritable flow strength is the best feature for drug influence flow prediction.
MuTHER (twin gene expression) KEGG (regulatory network) CMap (drug-gene relation)
Heritable/non-heritable effects Regulation flows in the network Drug influence genes Drug target preference Drug influence flows prediction Twin-ACE DAGRN Fig. 3 . A process flow chart of the relationship between data and experiments. Yellow nodes are the dataset we used. Green nodes are the information we extracted from the dataset. White nodes are the experiment we conducted. Our twin gene expression data is acquired from MuTHER 2 database. The data was measured on blood samples from 276 monozygotic and 442 dizygotic twins. All the gene expression data is centered and standardized. Hence, the expression vector of each gene has mean zero and unit variance. Heritable and non-heritable effects for each gene are estimated using Twin-ACE model.
Data pre-process
We combined a joint gene regulatory network (GRN) from 257 human signal pathways in KEGG pathway 14, 15 database. We selected the sub-network from GRN that contains genes from MuTHER and converted it into a DAGRN. We sorted the nodes based on their children count. We then removed edges conflicting with this order, that is to say edges pointing from lower ranked nodes to higher ranked nodes under the order. The transformed DAGRN from KEGG pathway contains 28600 directed edges and 3245 genes.
Drug target preference
We test the significance of the overlap between genes influenced by drugs and genes driven by strong heritable effects. 6100 drug instances from CMap database were used for the test. We calculate the heritability of each gene using the ACE parameters as h = a 2 a 2 +c 2 +e 2 . Hence, heritability is a value between 0 and 1 indicates how much the percentage of heritable effect in total variance of the gene. The genes with heritability over 0.5 are deemed heritable genes; genes with heritability under 0.2 are deemed non-heritable genes. There are 120 heritable genes and 2199 non-heritable genes. We performed a hypergeometric significance test. There are total U = 3249 genes, M = 120 of them are heritable. For each drug with N = 32 (top 1%) genes influenced, where K of them are heritable genes, we calculate the p-value as the probability of having K or more heritable genes in randomly chosen N samples from total U genes. If pvalue is smaller than a certain threshold, we deem the overlap between the genes influenced by the drug and heritable genes significant. We call this kind of drugs "heritable-gene-targeting drugs". We also performed the same significance test to identify "non-heritable-gene-targeting drugs".
The result is shown in Figure 4 . When we select p-value threshold as 0.001, there are 4 heritable-gene-targeting drugs and 1 non-heritable-gene-targeting drug. The names of the drugs and the constitution of the genes influenced by the drugs are shown in Figure 5 . Figure 4 shows dramatic difference in counts of heritable-gene-targeting drugs and nonheritable-gene-targeting drugs. Hence, current drugs are more likely to target a gene driven by strong heritable effects rather than strong non-heritable effects.
Drug influence flows prediction
We estimated the regulatory network built from DAGRN using the twin gene expression data from MuTHER database. Stimulate-Response matrix is calculated for 3245 genes in the regulatory network. We selected the threshold T = 0.3 to be the threshold for regulation flows and extracted 233 regulation flows. There are 212 different target genes and 164 different source genes. From the CMap, we found 77 regulation flows are true drug influence flows.
To validate our assumption that the regulation flow with high heritable flow strength is more likely to be a drug effective flow, three features are compared here as a classifier of drug influence flow:
• 1. Heritable flow strength of the regulation flow: G(s, t).
• 2. Non-heritable flow strength of the regulation flow: E(s, t).
• 3. Regulation flow strength of the regulation flow: S(s, t). For each feature, we selected a list of value thresholds from minimum to maximum of that feature value. If a known drug influence flow has feature value above the threshold, it is counted as a true-positive. The true-positive rate (TPR) is the ratio between true-positive count and total number of drug influence flows. If a regulation flow above the threshold is not a drug influence flow, it is counted as a false-positive. The false-positive rate (FPR) is the ratio between false-positive count and total number of regulation flows that are not drug influence flows. The TPRs and FPRs across all the thresholds construct receiver operating characteristic (ROC) curve. We use area-under-curve (AUC) as the performance metric. A higher AUC indicates the feature is better for predicting correct drug influence flows. The ROC curves for three features are plotted in Figure 6 . It is obvious from the result that using the feature heritable flow strength (AUC = 0.63) is much better than non-heritable flow strength (AUC = 0.38) and regulation flow strength (AUC = 0.44) for predicting drug influence flows.
We also listed the drug influence flows ranked by heritable and non-heritable flow strength in Table 1 
Discussion
In this paper, we answered the very first question in our paper: whether a drug aiming to perturb a disease phenotype should target genes whose expression is dominated by heritable or non-heritable factors? Even though the variance in expression of most genes in the blood sample are driven by non-heritable effects, our first experiment showed that drugs prefer to influence genes driven by strong heritable effects rather than non-heritable effects. We then extended this observation to the in the background of regulatory network, where we found the regulation flow with high heritable flow strength is more likely to be a drug influence flow than flows with high nonheritable strength. The answer to the question is clear from our experiment: a drug aiming to perturb a disease phenotype should target genes whose expression is dominated by heritable rather than non-heritable factors.
In both experiments, we identified the drugs targeting genes driven by strong heritable or non-heritable effects. These observations and discoveries can help us design drugs targeting more specific and precise regulation flows in the regulatory network to influence the final target gene's expression.
There are plenty of extensions for the current method. We can remove the DAGRN restriction and construct a model the general gene regulatory network with loops and undirected edges, as this is the most common gene regulation pathway. Another possible application is to use the Stimulation-Response matrix for any specific study in gene expression control problem with more constrained goals and resource limitations.
